The overall ORs for KRAS and GNAS mutation in IPMN patients were 71.240 (95 % CI 16.856–301.086; P < 0.001, Q = 1.810, I2 = 0.000) and 15.297 (95 % CI 4.544–51.498; P < 0.001, Q = 4.525, I2 = 11.611), respectively. This evidence concerns the gene GNAS and pancreatic intraductal papillary-mucinous neoplasm.